Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Protheroe

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Nature Communications|March 20, 2015
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolutionMichal Kovac, Carolina Navas, Stuart Horswell, et al.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.
Cancer Research|February 9, 2021
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Isaac Kitchen-Smith, Lingyun Xiong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Nature Communications|March 20, 2015
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolutionMichal Kovac, Carolina Navas, Stuart Horswell, et al.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Urology Oncology|June 4, 2019
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectivenessBeth S Woods, Eleftherios Sideris, Matthew R Sydes, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
Pageof 9